Sanofi SA (SNY) has released an update.
Sanofi’s new treatment for relapsing multiple sclerosis, frexalimab, has shown promising 48-week phase 2 results, including a high efficacy and low annual relapse rate, without lymphocyte depletion. Nearly all patients remained lesion-free, and the drug was well-tolerated, with Sanofi now commencing global phase 3 trials. Frexalimab represents a novel therapeutic approach, potentially addressing unmet needs in MS treatment.
For further insights into SNY stock, check out TipRanks’ Stock Analysis page.
